169 related articles for article (PubMed ID: 12650491)
1. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.
Carceles MD; Aleixandre F; Fuente T; López-Vidal J; Laorden ML
Eur J Anaesthesiol; 2003 Mar; 20(3):205-11. PubMed ID: 12650491
[TBL] [Abstract][Full Text] [Related]
2. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
3. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
4. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
5. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities.
Lugnier C; Gauthier C; Le Bec A; Soustre H
Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036
[TBL] [Abstract][Full Text] [Related]
6. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
9. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
Ellis JL; Conanan ND
J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.
Rousseau E; Gagnon J; Lugnier C
Mol Cell Biochem; 1994 Nov; 140(2):171-5. PubMed ID: 7898488
[TBL] [Abstract][Full Text] [Related]
11. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
12. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
13. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
14. Distinct profiles of phosphodiesterase isozymes in cultured cells derived from nonpigmented and pigmented ocular ciliary epithelium.
Bode DC; Hamel LT; Wax MB
J Pharmacol Exp Ther; 1993 Dec; 267(3):1286-91. PubMed ID: 8263791
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
16. Multiplicity within cyclic nucleotide phosphodiesterases.
Rybalkin SD; Beavo JA
Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
[No Abstract] [Full Text] [Related]
17. Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig.
Turner NC; Dolan JS; Grimsditch D; Lamb J; Worby A; Murray KJ; Coates WJ; Warrington BH
Br J Pharmacol; 1994 Apr; 111(4):1198-204. PubMed ID: 8032606
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
